How p53 Affects Chemotherapy in Ovarian Cancer
Author Information
Author(s): Carlos S. Moreno, Lilya Matyunina, Erin B. Dickerson, Nina Schubert, Nathan J. Bowen, Sanjay Logani, Benedict B. Benigno, John F. McDonald
Primary Institution: Emory University School of Medicine
Hypothesis
The study investigates whether p53-mediated cell-cycle-arrest inhibits the effectiveness of chemotherapy in ovarian carcinomas.
Conclusion
The study concludes that p53 loss-of-function mutations are associated with a more favorable clinical response to chemotherapy in ovarian cancer patients.
Supporting Evidence
- Patients with p53 loss-of-function mutations had a better response to chemotherapy.
- Gene expression profiles clustered into two distinct groups based on treatment history.
- The study identified specific genes that were significantly altered between the two groups.
Takeaway
This study found that some ovarian cancer cells can resist chemotherapy because of a gene called p53, and if we can stop p53 from working, the treatment might work better.
Methodology
The study used gene expression profiling and unsupervised clustering to analyze ovarian tumor samples from patients treated with chemotherapy.
Potential Biases
Potential bias due to the small sample size and the specific patient population studied.
Limitations
The study had a limited sample size for follow-up data, which may affect the statistical significance of the findings.
Participant Demographics
The average age of participants was 61, with a range from 41 to 84 years.
Statistical Information
P-Value
0.006
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website